ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.
“I have a background as a scientist although I am serving a different role now as the CEO. I feel very proud to have shown a good case of solid science leading to business,” stated Sang Hoon Lee, CEO and founder of ABL Bio Inc., which reached a major global out-licensing deal with Sanofi in January.
The potential $1.06bn deal marked the biggest licensing agreement signed so far by the Korean biotech, which has clinical-stage assets...
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
